Hologic (Nasdaq:HOLX) posted second-quarter results today that solidly exceeded the consensus forecast on Wall Street and increased its outlook for the rest of the year.
Marlborough, Massachusetts–based Hologic reported profits of $455.7 million, or $1.80 per diluted share, on sales of $1.436 billion for the three months ended March 26, 2022. That was a bottom-line decrease of 26.5% and sales decline of 6.6% compared with Q2 2021, primarily due to declining sales of COVID-19 diagnostics.
Adjusted to exclude one-time items, earnings per share were $2.07, $0.47 ahead of the Street, where analysts were looking for EPS of $1.60 on sales of $1.29 billion.